Canaccord analyst Whitney Ijem raised the firm’s price target on Ultragenyx (RARE) to $136 from $121 and keeps a Buy rating on the shares. The ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...

The Super Bowl logo has become more of a talking point among NFL fans over the last few seasons. Part of the reason for that is a conspiracy theory that the colors of the Super Bowl logo determine ...

OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. Emma Roth is a news writer ...

But the visual representation of this industry disruptor is not a swirling black-void logo à la OpenAI, or even a robot. Instead, it’s a friendly blue whale. This diverges from branding trends ...

On Monday, three logos were revealed to the public, one for each potential nickname, but NHL fans weren't particularly impressed by the latest round of options. Much of the criticism was focused ...

In addition, the company gets a decent amount of revenue from Dojolvi (approved for treating long-chain fatty acid oxidation disorders) and Evkeeza (FDA-approved for treating homozygous familial ...

The estimate indicates a change of -39.1% from the prior-year quarter. Analysts forecast 'Revenues- Evkeeza- US' to reach $45.64 million. The estimate points to a change of +90.2% from the year ...

Our international growth in 2024 was particularly impressive. We successfully launched Evkeeza in Europe, Canada, and Japan, while broadening access to our other commercial therapies in Latin ...